ALI & Pulmonary HA Deposition After SAH
ConditionSubarachnoid Haemorrhage (SAH)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorTianjin Medical University
About this trial
Acute lung injury is a common complication of subarachnoid hematoma (SAH), and a significant risk factor for death in patients with SAH. Unlike neurogenic pulmonary edema and pneumonia following brain injury, the clinical causes of pulmonary injury after SAH are not intracranial hypertension or pulmonary infection. Its occurrence is influenced by the release of catecholamines, the regulatory function of the hypothalamic-pituitary-adrenal (HPA) axis and systemic inflammatory response, but the specific mechanisms are still unclear. Therefore, delving into the pathological mechanisms of SAH-induced lung injury and developing therapeutic strategies based on the findings is of great importance to improve the prognosis of patients.
Abnormal accumulation of hyaluronic acid in the lungs has been reported to be closely related to the pathological progression of various pulmonary injury diseases, such as chest trauma, pulmonary infection and chronic obstructive pulmonary disease. From this, the present research is aimed to explore the levels and dynamic changes of hyaluronic acid in the bronchoalveolar lavage fluid and blood of patients with acute lung injury following SAH, and to analyze its correlation with the prognosis of pulmonary complications, thereby providing assistance for the clinical diagnosis and treatment of SAH.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 and 80 years old with independent behavior ability or authorized legal representative.
A documented diagnosis of SAH within 5 days.
A Hunt-Hess scale of Ⅳ or Ⅴ.
Absence of clinical and etiological evidence of pulmonary infection.
Disqualifiers
Pregnant or lactating women.
Present history of traumatic brain injury or intracranial hemorrhage.
Past history of neurological disorders, lung infection within the past six months, cancer, chronic cardiopulmonary diseases, hematological diseases or renal failure.
Have participated in clinical trials in the past 4 weeks.
Trial population
Estimated by statistical analysis, a total of 24 subjects were included from patients admitted to the neurosurgical intensive care unit of Tianjin Medical University General Hospital and the intensive care unit of Tianjin Huanhu Hospital due to aneurysmal SAH.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
24 Participants
are grouped into 1 trial groupGroup A: Subarachnoid Hemorrhage (SAH)
Trial outcomes
Primary outcomes
1
Hyaluronic acid level in bronchoalveolar lavage fluid after SAH
Hyaluronic acid level (ng/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Time frame
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH2
Inflammatory cytokines levels in bronchoalveolar lavage fluid after SAH
Inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) in bronchoalveolar lavage fluid at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Time frame
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAHSecondary outcomes
1
Serum hyaluronic acid level after SAH
Serum hyaluronic acid level (ng/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Time frame
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH2
Serum inflammatory cytokines levels after SAH
Serum inflammatory cytokines (IL-1β, TNF-α and IL-10) levels (pg/ml) at the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAH
Time frame
During the acute phase (1-5 days post-onset) and the chronic phase (10-14 days post-onset) of patients with SAHSponsors and contacts
Click on the lead sponsor to view all of their trials.
Tianjin Medical University
Lead sponsor
Tianjin Medical University General Hospital
Sponsor institution
Source ClinicalTrials.gov